Chronic Graft-versus-Host Disease (cGVHD)
cGVHD is a major late complication of allogeneic hematopoietic stem cell transplantation (HSCT). Donor immune cells attack host tissues, causing fibrosis and immune dysregulation affecting skin, eyes, mouth, lungs, liver, GI tract, and joints. Early recognition and tailored immunosuppression preserve organ function and quality of life.
Risk Factors
- Prior acute GVHD, peripheral blood stem cell grafts
- HLA mismatch, older donor/recipient age
- Donor parity, conditioning intensity
- Chronic infections (CMV) or immune reconstitution issues
Diagnosis & Staging
- NIH cGVHD scoring (0–3) for each organ (skin, mouth, eyes, GI, liver, lungs, joints/fascia, genital tract)
- Classic vs overlap syndrome (features of acute + chronic)
- Baseline PFTs (FEV1, DLCO) for lung involvement (bronchiolitis obliterans syndrome)
- Skin biopsy, ocular evaluation, liver enzymes, GI endoscopy as needed
Management Strategy
First-Line
- Systemic steroids (prednisone 0.5–1 mg/kg/day) + calcineurin inhibitor continuation/taper
- Topical therapies for mild organ involvement (steroids, tacrolimus, ocular lubricants)
Steroid-Refractory (SR) cGVHD
- Ruxolitinib (JAK1/2 inhibitor) improves overall response, reduces steroid need
- Belumosudil (ROCK2 inhibitor) for SR cGVHD after ≥2 prior lines
- Ibrutinib for SR cases with B-cell-driven disease
- Extracorporeal photopheresis (ECP) beneficial for skin/lung involvement
- Other agents: mycophenolate, sirolimus, methotrexate, rituximab, imatinib
Supportive & Organ-Specific Care
- Skin: emollients, UVA1/PUVA therapy, physical therapy for sclerotic changes
- Eyes: preservative-free lubricants, punctal plugs, cyclosporine drops, scleral lenses
- Mouth: topical steroids, dexamethasone rinses, dental prophylaxis
- Lungs: inhaled steroids/bronchodilators, macrolide therapy, pulmonary rehab
- GI: budesonide, beclomethasone, nutrition support
- Genital: topical estrogen, dilators, surgery for strictures
- Vaccinations when immune reconstitution allows (revaccination schedule post-HSCT)
Infection Prophylaxis
- Antiviral, antifungal, and PJP prophylaxis while immunosuppressed
- Monitor CMV/EBV; treat promptly
Living with cGVHD
- Track organ scores, medications, infections, PFTs, labs, physical therapy, ocular/oral symptoms, nutrition, vaccinations, and mental health
- Encourage daily stretching/exercise to prevent contractures
- Manage fatigue, pain, depression/anxiety with interdisciplinary support
- Discuss fertility considerations, contraception, pregnancy timing
Complications
- Opportunistic infections, sepsis
- Pulmonary fibrosis/bronchiolitis obliterans
- Hepatobiliary dysfunction
- Scleroderma-like skin changes, joint contractures
- Osteopenia, steroid diabetes, cataracts
Research & Future Directions
CAR-Treg therapies, IL-2/IL-2 analogs, microbiome modulation, and biomarker-driven tapering aim to induce tolerance with fewer side effects.
Experimental & Emerging Treatments
- Low-Dose IL-2 & Treg Expansion: Restores regulatory/effector balance.
- Mesenchymal Stromal Cell Infusions: Anti-inflammatory effect in refractory disease.
- JAK/TYK Combinations: Next-gen selective inhibitors to minimize cytopenias.
- Microbiome-Based Therapies: Fecal transplant, targeted probiotics to rebuild immune tolerance.
Track cGVHD with Diagnoza.care
Connect Every Specialist, Every Symptom – Log NIH organ scores, PFTs, skin measurements, ophthalmology/dental visits, immunosuppressant doses, infections, physical therapy, nutrition, vaccinations, and mental health metrics; capture side effects; and let the AI companion alert you to deterioration requiring prompt team response.
Medical Disclaimer: Informational only. Work with your transplant center for grading, immunosuppression strategy, infection prophylaxis, and long-term supportive care.
Sources: NIH Consensus Criteria for cGVHD, EBMT/ASBMT Guidelines, American Society for Transplantation and Cellular Therapy